Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.50    1.00 (1.55%)
Bid:
65.00
Ask:
65.90
Spread: 0.90 (1.385%)
Market Cap: £578.65m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Director/PDMR Shareholding

10 May 2018 18:18

RNS Number : 7330N
IP Group PLC
10 May 2018
 

FOR RELEASE ON

10 May 2018

 

IP Group plc - LTIP

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that it has made conditional awards of 5,025,302 ordinary shares of two pence each ("Shares") to its executive directors, other persons discharging managerial responsibilities ("PDMRs") and certain other employees under its Long Term Incentive Plan (the "LTIP").

 

The performance measures attaching to the 2018 awards are based on the achievement of targets linked to growth in the Company's "hard" net assets ("Hard NAV") and total shareholder return ("TSR") as described in the Directors' Remuneration Report of the Annual Report and Accounts. The starting point for the TSR target is 134.5p, being the one-month average closing price up to the date of grant. The starting point for the Hard NAV performance measure is the Group's audited Hard NAV at 31 December 2017 of £1,326.2m. The number of Shares conditionally awarded was calculated using the closing price on 9 May 2018 of 139.2p.

 

Assuming satisfaction of the conditions in full, the awards will ordinarily vest on or after 31 March 2021 and the Shares will be issued as soon as practicable after these dates. Any such Shares would be subject to a minimum two-year post-vesting holding period.

 

Conditional awards over 2,539,512 Shares have been made to the executive directors and other PDMRs, as set out in the table below, with awards over a further 2,485,790 to other of the Group's employees.

 

Executive Director/PDMR

Maximum number of Sharesconditionally awarded in respectof 2018 LTIP

Maximum number of conditionally awarded Shares outstanding at the date of this announcement

Alan Aubrey

894,397

2,415,852

David Baynes

395,115

1,547,028

Mike Townend

395,115

1,101,028

Greg Smith

395,115

1,080,489

Sam Williams

395,115

725,170

Mark Reilly

64,655

163,736

 

The number of Shares stated is the maximum number that could be issued to each executive director or PDMR upon full satisfaction of the performance conditions attaching to the awards.

As at the date of this announcement, a total of 12,651,184 Shares conditionally awarded to executive directors, other PDMRs and employees of IP Group remain outstanding under the IP Group LTIP and subject to performance conditions.

 

The Company currently has 1,059,144,595 Ordinary Shares in issue.

 

The following information is being disclosed pursuant to the requirements of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Alan AubreyMike TownendGreg SmithDavid BaynesSam WilliamsMark Reilly

2

Reason for the notification

a)

Position/status

Director Chief Executive OfficerDirector Chief Investment OfficerDirector Chief Financial OfficerDirector Chief Operating OfficerPDMR Managing Partner, Life SciencesPDMR Managing Partner, Technology

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IP Group plc

b)

Legal Entity Identifier

213800HG22UM138WFG43

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 2p each in IP Group plc

 ISIN: GB00B128J450

b)

Nature of the transaction

Grant of Options under the IP Group plc LTIP

c)

Currency

GBP

d)

Price(s) and volume(s)

Name(s)

Price(s)

Volume(s)

Alan Aubrey

Nil

894,397

Mike Townend

Nil

395,115

Greg Smith

Nil

395,115

David Baynes

Nil

395,115

Sam Williams

Nil

395,115

Mark Reilly

Nil

64,655

 

e)

Aggregated information

-Aggregated volume

- Price

- Aggregated total

 

Aggregated Number of Shares Granted Under the LTIP to Directors and PDMRs on 9 May 2018: 2,539,512

Price: £ nil

f)

Date of the transaction

9 May 2018.

g)

Place of the transaction

London Stock Exchange, Main Market

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

 

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGGUQGAUPRGMU
Date   Source Headline
29th Oct 20212:02 pmRNSPortfolio co Hinge Health completes $400m round
28th Oct 20216:21 pmRNSTransaction in Own Shares
27th Oct 20215:43 pmRNSDirector/PDMR Shareholding
27th Oct 20215:25 pmRNSTransaction in Own Shares
26th Oct 20215:56 pmRNSTransaction in Own Shares
25th Oct 20216:28 pmRNSTransaction in Own Shares
25th Oct 20217:00 amRNSAdditional fair value gain of £27.5m
22nd Oct 20216:29 pmRNSTransaction in Own Shares
21st Oct 20216:00 pmRNSTransaction in Own Shares
20th Oct 20215:56 pmRNSTransaction in Own Shares
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.